Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

Axel Heidenreich; David Pfister; Axel Merseburger; Georg Bartsch

doi:10.1016/j.eururo.2013.05.021

Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

Axel Heidenreich^*, David Pfister, Axel Merseburger, Georg Bartsch

^*Corresponding author for this work

Clinic of Urology

42 Citations (Scopus)

Original language	English
Journal	European Urology
Volume	64
Issue number	2
Pages (from-to)	260-265
Number of pages	6
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2013.05.021
Publication status	Published - 08.2013

Funding

Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose.

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2013.05.021

Cite this

@article{486f68ba3c2742d7be52892d1d8b13bd,

title = "Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know",

author = "Axel Heidenreich and David Pfister and Axel Merseburger and Georg Bartsch",

note = "Funding Information: Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2013",

month = aug,

doi = "10.1016/j.eururo.2013.05.021",

language = "English",

volume = "64",

pages = "260--265",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

AU - Heidenreich, Axel

AU - Pfister, David

AU - Merseburger, Axel

AU - Bartsch, Georg

N1 - Funding Information: Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2013/8

Y1 - 2013/8

UR - https://www.scopus.com/pages/publications/84879969831

U2 - 10.1016/j.eururo.2013.05.021

DO - 10.1016/j.eururo.2013.05.021

M3 - Editorial

C2 - 23706522

AN - SCOPUS:84879969831

SN - 0302-2838

VL - 64

SP - 260

EP - 265

JO - European Urology

JF - European Urology

IS - 2

ER -

Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Cite this